Here’s my Chat with the CBO of Immunocore, the Only EU Biotech to have ever raised €300M in one Round

21/12/2015 - 5 minutes

Last Thursday at Genesis in London, I had the chance to meet with Eva-Lotta Allan, CBO of Immunocore (and previously from Ablynx). After a last-minute confirmation before the event, we came to meet and it helped me understand why Immunocore could be the next Biotech success-story in Europe…

I’m sure you’ve heard of Immunocore this year. This Oxford-based Biotech company is developing TCR-based immuno-oncology treatments and has raised nearly €300M ($320M) in its last round of fundraising – a pure anomaly for the European standard.

Even worldwide, this is the second private biggest fundraising ever for a Biotech company after Boston-based Moderna (my exclusive interview of the CEO here).

After being in London, I did a stop in Paris and talked with a friend at the VC Edmond de Rothschild. He told me they were impressed by the company:

“Immunocore could become the next Amgen“.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: